CMS Raises Remodulin Reimbursement Payments To Distributors
This article was originally published in The Pink Sheet Daily
Executive Summary
The payment ceiling for distribution of the drug to Medicare beneficiaries will be raised to $61.75 per milligram, CMS says. Remodulin manufacturer United Therapeutics hails the decision as a “favorable resolution” to the “under-reimbursement situation” in 2004.